Postoperative Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: Impact of High-Dose Corticosteroid Nasal Spray
| Autor: | Takeshi Kusunoki, Akihito Shiozawa, Yoshinobu Kidokoro, Noritsugu Ono, Remi Hibiya, Hirotomo Homma, Katsuhisa Ikeda, Hiroko Okada, Shin Ito |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class medicine.medical_treatment Nostril Mometasone furoate lcsh:Medicine Gastroenterology intranasal administration corticosteroids 03 medical and health sciences 0302 clinical medicine Internal medicine Eosinophilic medicine otorhinolaryngologic diseases Nasal polyps chronic rhinosinusitis nasal polyps 030223 otorhinolaryngology Adverse effect Original Research business.industry lcsh:R medicine.disease lcsh:Otorhinolaryngology lcsh:RF1-547 medicine.anatomical_structure Otorhinolaryngology Nasal spray 030220 oncology & carcinogenesis adverse effects Corticosteroid Nasal administration business medicine.drug |
| Zdroj: | International Archives of Otorhinolaryngology, Vol 23, Iss 01, Pp 101-103 (2019) International Archives of Otorhinolaryngology International Archives of Otorhinolaryngology v.23 n.1 2019 Fundação Otorrinolaringologia (FORL) instacron:FORL |
| ISSN: | 1809-4864 1809-9777 |
| DOI: | 10.1055/s-0038-1668515 |
| Popis: | Introduction Eosinophilic chronic rhinosinusitis (ECRS) is characterized by an eosinophilic inflammation driven by Th2-type cytokines. Glucocorticosteroids are the most common first-line treatment for ECRS with nasal polyps. Objective We have evaluated the long-term treatment with double-dose intranasal corticosteroids in refractory ECRS nasal polyps resistant to the conventional dose and assessed the risk of adverse systemic effects Methods Sixteen subjects were enrolled in this study. All subjects had ECRS after endoscopic sinus surgery that resulted in recurrent mild and moderate nasal polyps and were undergoing a postoperative follow-up application of mometasone furoate at a dose of 2 sprays (100 μg) in each nostril once a day (200 μg). All the patients were prescribed mometasone furoate, administered at a dose of 2 sprays (100 μg) in each nostril twice a day (400 μg) for 6 months. Results The average scores of the symptoms during the regular dose of intranasal steroid treatment were 5.2 ± 2.2, but 6 months after the high-dose application, they had significantly decreased to 2.5 ± 1.4 (p Conclusion Doubling the dose of the nasal topical spray mometasone furoate might be recommended for the treatment of recurrent nasal polyps in the postoperative follow-up of intractable ECRS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|